Latanoprost stimulates secretion of matrix metalloproteinases in tenon fibroblasts both in vitro and in vivo

被引:34
作者
Mietz, H [1 ]
Esser, JM [1 ]
Welsandt, G [1 ]
Kociok, N [1 ]
Hueber, A [1 ]
Joussen, A [1 ]
Esser, P [1 ]
Kriegstein, GK [1 ]
机构
[1] Univ Cologne, Dept Ophthalmol, D-50924 Cologne, Germany
关键词
D O I
10.1167/iovs.02-0462
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE. To investigate the presence and the possible role of different matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in Tenon capsule fibroblasts. These enzymes are essential for the control of tissue remodeling in the context of wound repair. This aspect is important to further the understanding of and possibly to influence the scarring process of filtering blebs after glaucoma surgery. METHODS. Untreated and latanoprost-treated human Tenon fibroblasts were examined for the presence of MMPs and TIMPs on the mRNA and protein levels. Assays performed included RT-PCR, real-time RT-PCR, immunocytochemistry, Western blot analysis, flow cytometry, and zymography. To investigate the changes in vivo, conjunctival specimens of rabbits treated with latanoprost eye drops were examined by immunohistochemistry. RESULTS. In all assays, both MMP-3 and TIMP-2 were detected. With the real-time RT-PCR technique, MMP-1, -2, -3, -7, -9, and -14 and TIMP-1 and -2 were detected. An upregulation of MMP-3 and TIMP-2 after latanoprost treatment of the fibroblasts was shown and found to occur on the mRNA and the protein levels. The upregulation of MMP-3 and TIMP-2 was confirmed in vivo. CONCLUSIONS. Tenon fibroblasts contain the ability on the mRNA level to synthesize all enzymes of the MMP and TIMP family that are related to remodeling of the extracellular matrix. The levels of MMP-3 and TIMP-2 increase after treatment with latanoprost. Tenon fibroblasts may be the target cells for attempts to influence the tissue levels of MMPs and TIMPs in the context of conjunctival wound healing after glaucoma surgery.
引用
收藏
页码:5182 / 5188
页数:7
相关论文
共 42 条
[1]  
ADDICKS EM, 1983, ARCH OPHTHALMOL-CHIC, V101, P795
[2]  
Agapova OA, 2001, GLIA, V33, P205, DOI 10.1002/1098-1136(200103)33:3<205::AID-GLIA1019>3.0.CO
[3]  
2-D
[4]  
Broadway D, 1995, J Glaucoma, V4, P136, DOI 10.1097/00061198-199504000-00012
[5]   ADVERSE-EFFECTS OF TOPICAL ANTIGLAUCOMA MEDICATION .2. THE OUTCOME OF FILTRATION SURGERY [J].
BROADWAY, DC ;
GRIERSON, I ;
OBRIEN, C ;
HITCHINGS, RA .
ARCHIVES OF OPHTHALMOLOGY, 1994, 112 (11) :1446-1454
[6]   ADVERSE-EFFECTS OF TOPICAL ANTIGLAUCOMA MEDICATION .1. THE CONJUNCTIVAL CELL PROFILE [J].
BROADWAY, DC ;
GRIERSON, I ;
OBRIEN, C ;
HITCHINGS, RA .
ARCHIVES OF OPHTHALMOLOGY, 1994, 112 (11) :1437-1445
[7]   TRABECULECTOMY - PRELIMINARY REPORT OF A NEW METHOD [J].
CAIRNS, JE .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1968, 66 (04) :673-&
[8]  
COSTA VP, 1993, OPHTHALMIC SURG LAS, V24, P152
[9]   EFFECT OF TNF, IL-1, AND IL-6 ON THE PROLIFERATION OF HUMAN TENONS CAPSULE FIBROBLASTS IN TISSUE-CULTURE [J].
CUNLIFFE, IA ;
RICHARDSON, PS ;
REES, RC ;
RENNIE, IG .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1995, 79 (06) :590-595
[10]  
Di Girolamo N, 2000, INVEST OPHTH VIS SCI, V41, P671